BIIB092

DRUG5 trials

Sponsors

Biogen, University of California, San Francisco

Conditions

Alzheimer's DiseaseCorticobasal Degeneration SyndromeFrontotemporal Lobar Degeneration With Tau InclusionsMAPT Mutation Carriers, SymptomaticNonfluent Aphasia, ProgressivePrimary TauopathiesProgressive Supranuclear PalsySupranuclear Palsy, Progressive

Phase 1

Multiple Ascending Dose Study of Intravenously Administered BMS-986168 (BIIB092) in Patients With Progressive Supranuclear Palsy

CompletedNCT02460094

BiogenProgressive Supranuclear Palsy

Start: 2015-10-02End: 2016-10-19Updated: 2018-09-04

Extension Study of BIIB092 in Participants With Progressive Supranuclear Palsy (PSP) Who Participated in CN002003

TerminatedNCT02658916

BiogenSupranuclear Palsy, Progressive

Start: 2016-02-22End: 2020-03-31Updated: 2020-05-18

BIIB092 in Primary Tauopathies: CBS, nfvPPA, sMAPT, and TES

TerminatedNCT03658135

University of California, San FranciscoCorticobasal Degeneration Syndrome, Frontotemporal Lobar Degeneration With Tau Inclusions, MAPT Mutation Carriers, Symptomatic +3

Start: 2018-09-12End: 2019-12-13Updated: 2019-12-19

Phase 2

Study of BIIB092 in Participants With Progressive Supranuclear Palsy

TerminatedNCT03068468

BiogenSupranuclear Palsy, Progressive

Start: 2017-06-01End: 2020-02-07Updated: 2020-12-21

Phase 2 Study of BIIB092 in Participants With Early Alzheimer's Disease

TerminatedNCT03352557

BiogenAlzheimer's Disease

Start: 2018-05-03End: 2021-08-30Updated: 2022-11-08

Related Papers

Longitudinal cognitive outcomes in two progressive supranuclear palsy clinical trials

Alzheimer s & Dementia2026-06-26

Planimetric and Linear MRI Markers for Progressive Supranuclear Palsy Classification: A Large Multicohort International Study.

2026-06-01

Brain Atrophy Does Not Predict Clinical Progression in Progressive Supranuclear Palsy

Movement Disorders2025-08-303 citations

Montreal cognitive assessment as a cognitive outcome measure in progressive supranuclear palsy

Frontiers in Neurology2024-12-042 citations

Magnetic Resonance Imaging Measures to Track Atrophy Progression in Progressive Supranuclear Palsy in Clinical Trials

Movement Disorders2024-06-0217 citations

Assessment of Efficacy and Safety of Zagotenemab: Results From PERISCOPE-ALZ, a Phase 2 Study in Early Symptomatic Alzheimer Disease.

2024-02-2216 citations

TANGO: a placebo-controlled randomized phase 2 study of efficacy and safety of the anti-tau monoclonal antibody gosuranemab in early Alzheimer’s disease

Nature Aging2023-11-2763 citations

Development of a cognitive composite for measuring change in progressive supranuclear palsy.

2021-10-125 citations

Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial.

2021-08-12104 citations

Does the <scp>Anti‐Tau</scp> Strategy in Progressive Supranuclear Palsy Need to Be Reconsidered? Yes

Movement Disorders Clinical Practice2021-08-072 citations

P1‐051: PARTICIPANT BASELINE CHARACTERISTICS IN PASSPORT, A PHASE 2 STUDY OF THE EFFICACY AND SAFETY OF BIIB092 FOR PROGRESSIVE SUPRANUCLEAR PALSY

Alzheimer s & Dementia2019-07-013 citations

Safety of the tau-directed monoclonal antibody BIIB092 in progressive supranuclear palsy: a randomised, placebo-controlled, multiple ascending dose phase 1b trial.

2019-06-01109 citations

Antibody-based immunotherapies for Parkinsonian syndromes

Neural Regeneration Research2019-01-014 citations

P3‐033: RANDOMIZED, DOUBLE‐BLIND, PLACEBO‐CONTROLLED STUDY TO ASSESS TREATMENT OF BIIB092 IN SUBJECTS WITH EARLY ALZHEIMER'S DISEASE: TANGO PHASE 2 STUDY DESIGN

Alzheimer s & Dementia2018-07-011 citations

Efficacy and Safety of BIIB092 in Patients with Progressive Supranuclear Palsy: PASSPORT Phase 2 Study Design (P6.073)

Neurology2018-04-106 citations